Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years

NCT03338296 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT03338296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03338296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years
Lead sponsor
Eisai Inc.
Phase
Phase 4
Overall status
Terminated
Start date
September 28, 2017
Completion date
April 3, 2020
Enrollment
278 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

obesity